ML-004 (IR)/(ER) tablet

DRUG2 trials

Sponsors

MapLight Therapeutics

Conditions

Autism Spectrum Disorder

Phase 2

ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)

CompletedNCT05081245

MapLight TherapeuticsAutism Spectrum Disorder

Start: 2022-09-13End: 2026-04-17Updated: 2026-05-19

ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)

Active, not recruitingNCT05889273

MapLight TherapeuticsAutism Spectrum Disorder

Start: 2023-06-01End: 2027-12-01Target: 120Updated: 2026-07-20